# Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients

> **NCT01712438** · PHASE3 · COMPLETED · sponsor: **Octapharma** · enrollment: 110 (actual)

## Conditions studied

- Severe Hemophilia A

## Interventions

- **BIOLOGICAL:** Human cl rhFVIII

## Key facts

- **NCT ID:** NCT01712438
- **Lead sponsor:** Octapharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2018-12-14
- **Final completion:** 2019-12-20
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2021-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01712438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01712438, "Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01712438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*